Please login to the form below

Not currently logged in
Email:
Password:

Zepatier

This page shows the latest Zepatier news and features for those working in and with pharma, biotech and healthcare.

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks

Discontinues its new-generation treatments but Zepatier is still making headway. Merck &Co has decided to exit hepatitis C virus (HCV) drug development, making its $3.85bn deal to buy Idenix ... The decision leaves Merck with Zepatier

Latest news

More from news
Approximately 6 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Brandcast Health

Brandcast Health is a digital MedComms and patient-engagement agency who help our clients create and share engaging content. Our innovative...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics